As of November 6, 2026, Avalyn Pharma Inc. is a publicly traded company (Nasdaq: AVLN). The largest holder reporting an active stake on Schedule 13D is SR One Capital Management, LLC, at 7.5%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Fidelity (FMR) (13.2%), Novo Holdings A/S (8.8%), Perceptive Advisors (6%) (Schedule 13D, May 8, 2026).
Is this your company?
About to sign with, pay or invest in Avalyn Pharma Inc.? See the free Snapshot first.
Free to see. No signup.
Is Avalyn Pharma Inc. a real, registered company?
- Avalyn Pharma Inc. files with the SEC under CIK 1540171 (its SEC filings).
- Its shares are listed under the ticker AVLN on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Boston, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Avalyn Pharma Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Novo Holdings A/S (filed 2026-08-14).
Who are Avalyn Pharma Inc.'s owners and officers?
Avalyn Pharma Inc.: incorporated in Delaware; business address in Boston, Massachusetts; industry Pharmaceutical Preparations (Schedule 13G, 2026-08-14).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2023-10-10)
- : Director (Form D, 2023-10-10)
- : Director (Form D, 2023-10-10)
- : Director (Form D, 2023-10-10)
- : Director (Form D, 2023-10-10)
- : Director (Form D, 2023-10-10)
- : Director (Form D, 2023-10-10)
- : Director (Form D, 2023-10-10)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-08-14 | Novo Holdings A/S | 8.8% |
| Schedule 13G, 2026-08-11 | Norwest Venture Partners Xv, LP | 5.1% |
| Schedule 13G/A, 2026-08-06 | Fmr LLC | 13.2% |
| Schedule 13D, 2026-05-08 | Sr One Capital Management, LLC | 7.5% |
| Schedule 13D, 2026-05-08 | Suvretta Capital Management, LLC | 5.6% |
| Schedule 13G, 2026-05-07 | Perceptive Advisors LLC | 6% |
| Schedule 13G, 2026-05-05 | Fmr LLC | 11.5% |
Questions about who owns Avalyn Pharma Inc.
Who owns Avalyn Pharma Inc.?
On this page, 6 holders' latest ownership filings report 5% or more of Avalyn Pharma Inc.: Fmr LLC (13.2%, Schedule 13G/A, filed 2026-08-06), Novo Holdings A/S (8.8%, Schedule 13G, filed 2026-08-14), Sr One Capital Management, LLC (7.5%, Schedule 13D, filed 2026-05-08), Perceptive Advisors LLC (6%, Schedule 13G, filed 2026-05-07) and Suvretta Capital Management, LLC (5.6%, Schedule 13D, filed 2026-05-08); 1 more is listed above.
Who are the largest shareholders of Avalyn Pharma Inc.?
By the share each holder's latest filing reports, the largest holders of Avalyn Pharma Inc. on this page are Fmr LLC (13.2%), Novo Holdings A/S (8.8%) and Sr One Capital Management, LLC (7.5%).
When did Fmr LLC buy into Avalyn Pharma Inc.?
The filings give report dates, not purchase dates. The earliest filing from Fmr LLC on this page is the Schedule 13G, filed 2026-05-05, reporting 11.5%; its latest, Schedule 13G/A filed 2026-08-06, reports 13.2%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 7 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Avalyn Pharma Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Avalyn Pharma Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Avalyn Pharma Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Avalyn Pharma Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- Novo Holdings A/S, a 10% owner: 3,883,289 shares (8.8% of shares outstanding) (Form 4, 2026-05-05).
- , a 10% owner: 3,308,649 shares (7.5% of shares outstanding), held indirectly through a see note 4, on a joint filing (Form 4, 2026-05-01).
- SR One Capital Management, LLC, a 10% owner: 3,308,649 shares (7.5% of shares outstanding), held indirectly through a see note 4, on a joint filing (Form 4, 2026-05-01).
- Fidelity (FMR), a 10% owner: 2,284,535 shares (5.2% of shares outstanding), held indirectly through F-Prime Capital Partners Healthcare Fund V LP (Form 4, 2026-05-05).
- , a director: 2,186,562 shares (4.9% of shares outstanding), held indirectly through a see note 2 (Form 4, 2026-05-01).
Shares outstanding: 44,333,095 as of 2026-08-31, from the company's latest SEC cover page.
How much has Avalyn Pharma Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2023-10-10 | $189.18M | $189.18M |
Latest IPO step: Avalyn Pharma Inc. filed its final IPO prospectus, ticker AVLN (424B4, 2026-04-30).
IPO filings: 424B4, 2026-04-30, S-1/A, 2026-04-29, S-1/A, 2026-04-23, S-1, 2026-04-08; ticker AVLN on Nasdaq Global Select Market.
Keep reading
More on Avalyn Pharma Inc. and the records around it.
Avalyn Pharma Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
Companies that share a holder
- SR One Capital Management, LLC also filed stake reports on 6 other companies: ADARx Pharmaceuticals, Inc. (Oct 2026), Zenas BioPharma, Inc. (Aug 2026), Veradermics, Inc. (Aug 2026)
- Novo Holdings A/S also filed stake reports on 11 other companies: Hemab Therapeutics Holdings, Inc. (Aug 2026), Obsidian Therapeutics, Inc. (Aug 2026), MAPLIGHT THERAPEUTICS, INC. (Jul 2026)
- SUVRETTA CAPITAL MANAGEMENT, LLC also filed stake reports on 22 other companies: Veradermics, Inc (Aug 2026), Abeona Therapeutics Inc. (Aug 2026), Fulcrum Therapeutics, Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/avalyn-pharma